Interested in owning StemCellPatents.com? Contact info@stemcellpatents.com.
Patents (1436 Stem Cell Patents)

Angiogenically effective unit dose of FGF-2 and method of use

Patent Number: 7,541,333

Date of First Priority Issue: Tuesday October 13th, 1998
Date Issued: Tuesday June 2nd, 2009
Assignee: Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA)
Inventors: Whitehouse; Martha Jo (San Francisco, CA)

From Class: Expansion
Comments: No comments

Stimulation of therapeutic angiogenesis offers great potential, not only for the obvious conditions such as critical limb ischemia and angina, but also for other indications post-stroke recovery and liver failure.  Methods of stimulating angiogenesis range from administration of endometrial regenerative cells, to caloric restriction, to use of stem cell mobilizers.

The current patent covers the administration of fibroblast growth factor-2 (FGF-2 or basic fibroblast growth factor) at specific concentrations for the treatment of congestive heart failure. 

The first independent claim covers:

"A method for treating a human patient for congestive heart failure, comprising administering a single unit dose of a therapeutically effective amount of a recombinant FGF-2 or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for said congestive heart failure, said therapeutically effective amount being about 0.2 .mu.g/kg to 48 .mu.g/kg of patient weight, wherein said recombinant FGF-2 comprises the sequence set forth in SEQ ID NO: 2, and wherein said angiogenically active mutein thereof has at least 90% sequence identity to SEQ ID NO: 2"

In the dependent claims various concentrations of heparin (remember FGF-2 is a heparin binding cytokine), sequences of administration, and routes of administration are covered.

The possibility of using FGF-2 in combination with other types of adult stem cells may offer, in our opinion, a potent method of overcoming some of the previous hurdles that the field of therapeutic angiogenesis has faced previously.

View this patent on the USPTO website.

Added to StemCellPatents.com on Monday June 8th, 2009

Social & Bookmarking:Digg 'Angiogenically effective unit dose of FGF-2 and method of use ' Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to del.icio.us Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to Technorati Stumble 'Angiogenically effective unit dose of FGF-2 and method of use ' Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to Furl Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to Reddit Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to Blinklist Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to Ma.gnolia Share 'Angiogenically effective unit dose of FGF-2 and method of use ' on Facebook Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to Google Add 'Angiogenically effective unit dose of FGF-2 and method of use ' to Yahoo Web 

Add Comment

You must be signed-in to add your comments.

Sign-in now or Join the StemCellPatents.com Community for free.



Home | News | Patents | Products | Jobs | Links | Search | Journal | RSS

About | Advisory Board | Newsletter | Advertise | Contact | Sitemap | Privacy Policy | Terms of Use

Copyright © 2006 - 2019 StemCellPatents.com - All rights reserved. - Toronto Web Design

StemCellPatents.com V2.10